

Sterility Assurance & Quality Risk Management Conference





**Sterility Assurance & Quality Risk
Management Conference**

**October
8th & 9th**



Determination of Microbial Incubation Time when following USP<73> Guidance

Dana Nutter
Senior Scientist
Charles River Laboratories



General Questions:

1. Who here works with **short-life** products?

- Compounded sterile preparations (CSPs)
- Positron emission tomographic (PET) products
- Cell and gene therapies

2. Are **rapid/alternative microbial detection methods** utilized at your facility?

- ATP-bioluminescence
- Respiration-based methods
- Solid phase cytometry

3. If rapid methods are not being utilized, why not?

- Difficult to validate
- Associated costs / resources



Why Consider Rapid Detection Methods?

- Faster time-to-result
- Objective result readings
- Reduced manufacturing costs
- Data integrity
- Earlier corrective actions
- Faster product release



Challenges with conventional sterility testing for short-life products

- Timing: Short-Life Products (ATMPs, Cell & Gene Therapies) & compounded products – At-risk release
- Sample Size: Small volumes and batch size for ONE personalized (autologous) therapy
- Matrices: May contain live cells (high cell densities) which may cause turbidity in culture media or interfere with microbial growth



Industry Guidance for Short-Life Products & RMMs

- [Ph. Eur. 2.6.27](#) Microbiological Examinations of Cell-Based Preparation
- [Ph. Eur. 5.1.6](#) Alternative Methods for Control of Microbiological Quality
- [USP <1071>](#) Rapid Microbial Tests for Release of Sterile Short-Life Products: A Risk-Based Approach
- [USP <1223>](#) Validation of Alternative Microbiological Methods (PDA TR 33, Ph. Eur. 5.1.6)

Official August 2025:

- [USP <72>](#) Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products
- [USP <73>](#) ATP Bioluminescence-Based Microbiological Methods for the Detection of Contamination in Short-Life Products




Sterility Assurance & Quality Risk Management Conference

October 8th & 9th



History of ATP-Bioluminescence





Regulatory Pathways for Short-Life Products

Previous Approach for Alternative Methods

- ✓ Feasibility/Compatibility
- ✓ Method Suitability
- ✓ Ruggedness/Repeatability
- ✓ Robustness
- ✓ Equivalence
- ✓ Limit of Detection
- ✓ Specificity

Revised Approach per USP <73>

- ✓ Feasibility/Compatibility
- ✓ Method Suitability
- ✓ Incubation Time Study

USP <73> could enable adoption by reducing validation time and costs associated with an extensive validation



USP General Chapter <73>

Official Date: 01-Aug-2025

“ATP Bioluminescence-Based Microbiological Methods for the Detection of Contamination in Short-Life Products”

- Provides risk-based guidelines for alternative sterility testing with the use of ATP methods for rapid detection of viable microorganisms in short-life products
- Determination of the [Incubation Time of the Product](#) based on the slowest growing microorganism
- Compatible for both direct inoculation and membrane filtration methods



USP General Chapter <73>

• Generation Time (G)

- Slowest-growing microorganism in the presence of product to establish the incubation time of microbial detection.
 - t = time during exponential growth phase.
 - N= the avg CFU at the **end** of the exponential growth phase
 - N₀=the avg CFU at the **start** of the exponential growth phase

$$G = \frac{t}{3.3 \times \log_{10}(N/N_0)}$$

• Incubation Time (T)

- Calculated based on the time of detection with **ATP-bioluminescence test (t_{ttd})** and the calc. G plus a safety margin.

$$T = t_{ttd} + \log_2(10) \times G$$




Figure 1. Growth phase curve.


In the figure above, t = 8 h, N₀ = 64 CFU/mL, N = 4.2 × 10⁶ CFU/mL, and G would be calculated as 0.5 h.



ATP-Bioluminescence Foundation

- Adenosine triphosphate (ATP) is present in all living cells, including bacteria, yeasts, and fungi.
- Standard ATP assays use enzyme luciferase to catalyse microbial ATP and produce light
- Light generated is measured using a luminometer (displayed as Relative Light Units)

- What about products that may contain their own ATP?






Cell-Based Sample Prep for ATP Testing

1. Prepare sample using compendial TSB/FTM and incubate accordingly
2. Vortex sample and transfer an aliquot to treatment solution to lyse the mammalian cells
3. The Celsis Adapt™ system draws the sample through a sterile, hollow fiber tip - **Physical removal of cellular debris and background ATP**
4. The microbial cells are captured on the hollow fibers
5. Separate concentration port allows sterile, pressurized concentrating solution to be pushed through tip and **removes microbial cells from the tip**
6. The sample is collected, which contains the **microbial cells**


If samples do not contain mammalian cells, this process can be skipped, and testing with ATP-bioluminescence can be completed directly from the incubated samples.



Celsis Adapt™ Instrument



Workflow for Testing Cell-Based Samples





**Sterility Assurance & Quality Risk
Management Conference**

**October
8th & 9th**




Applying USP<73>

Using Celsis Adapt™ Cell for ATP-Bioluminescence



Sample Feasibility / Compatibility

- Are cell-based products compatible with ATP bioluminescence?






Method Suitability

- Products tested: CAR-T cells, viral vectors, plasmids
- Microorganisms tested in the presence of product as well as without product
 - *S. aureus*, *P. paraeruginosa*, *C. sporogenes*, *C. acnes* – FTM 30-35 °C
 - *B. spizizenii*, *C. albicans*, *A. brasiliensis* – TSB 20-25 °C
- Test microorganisms inoculated at not more than 10 CFU
- Test at multiple time points to determine exponential growth
- Calculate the generation time for the slowest growing microorganism and the incubation time for the products



Example of growth curve calculations - CFU

Product: CAR-T Cells (2×10^6 cells/mL)
Microorganism: *Bacillus spizizenii* (10 CFU/mL)



1. Identify the exponential phase
 - $N = 52,200$
 - $N_0 = 675$
 - $t = 6$
2. Use the above variables to calculate the Generation Time (G):


$$G = \left(\frac{t}{3.3 \times \log_{10}(N/N_0)} \right)$$

$$G = 0.96 \text{ hours}$$



Example of growth curve calculations – CFU continued

Product: CAR-T Cells (2×10^6 cells/mL)
Microorganism: *Bacillus spizizenii* (10 CFU/mL)



1. Calculated G from previous slide
G = 0.96 hours
2. Determine first timepoint in which rapid method detected the microorganism.
 $t_{\text{ttd}} = 24$ hours
3. Use the above variables to calculate Incubation Time (T)

$$T = t_{\text{ttd}} + \log_2(10) \times G$$


$$\mathbf{T = 27.2 \text{ hours} / 1.13 \text{ days}}$$

Conclusion: The calculated Incubation Time is less than 2 days.



Growth Curve Calculations - RLU

Product: CAR-T Cells
Microorganism: *Bacillus spizizenii*
Reagent Kit: Celsis Adapt™ Cell




1. Calculations based on RLU:
 - $N = 491,968$
 - $N_0 = 3,277$
 - $t = 6$
2. Generation Time (G) = 0.84 hours
3. Time point of ATP detection (t_{ttd}) = 24
4. Incubation Time $T = 26.8$ hours / 1.12 days

Conclusion: Incubation Time based on CFU = 27.2 hours / 1.13 days
Incubation Time based on RLU = 26.8 hours / 1.12 days



Product Incubation Time Summary

Calculated Incubation Time (T) per Microorganism - RLU and CFU for CAR-T Cells




Slowest growing microorganism – *C. acnes* Calc. Incubation Time for CAR-T product = <5 days

Compendial sterility test = Day 14, Celsis sterility test = Day 7, USP<73> = Day 5



CAR-T Production Workflow



www.cellgenetherapyreview.com



Observations

- Potential challenges with strict anaerobic cultures
 - When not using continuous monitoring
 - Slower growth observed
- Localized colony growth of molds in enrichment broth
- Challenges with achieving less than 10 CFU for inoculum
- Need to consider 8-hour shift and data collection requirements for robust growth curves
- Delayed results when needing to wait for colony growth versus collecting real time data with the rapid method



Conclusions

- USP <73> provides a clear compendial pathway for the use of ATP-Bioluminescence for rapid sterility testing
- New general chapters will pave the way for implementation of rapid detection methods for sterile manufacturing



Sterility Assurance & Quality Risk Management Conference

October
8th & 9th



Contact Information

Charles River

1-877-CRIVER-1

askcharlesriver@crl.com

www.criver.com